NCT01086306
- Conditions
- Diabetes Mellitus, Diabetes Mellitus, Type 2, Endocrine System Diseases, +3 more
- Locations
-
Not specified
Clinical trial condition
Diabetes Mellitus, Type 2
Explore clinical trials studying Diabetes Mellitus, Type 2. Study availability and eligibility vary by location and protocol.
2,679 public trials
158 recruiting studies
Diabetes Mellitus, Type 2 trial results
NCT01553968
- Conditions
- Diabetes Mellitus, Diabetes Mellitus, Type 2, Endocrine System Diseases, +3 more
- Locations
-
- Maastricht University Medical Center Maastricht, Limburg, Netherlands
NCT02121483
- Conditions
- Diabetes Mellitus, Diabetes Mellitus, Type 2, Endocrine System Diseases, +3 more
- Locations
-
- 1245.87.01013 Boehringer Ingelheim Investigational Site New Haven, Connecticut, United States
- 1245.87.01004 Boehringer Ingelheim Investigational Site Boston, Massachusetts, United States
- 1245.87.01002 Boehringer Ingelheim Investigational Site Toledo, Ohio, United States
- 1245.87.01012 Boehringer Ingelheim Investigational Site Philadelphia, Pennsylvania, United States
Completed
Finding a Safe and Effective Dose of Linagliptin in Pediatric Patients With Type 2 Diabetes
NCT01342484
- Conditions
- Diabetes Mellitus, Diabetes Mellitus, Type 2, Endocrine System Diseases, +3 more
- Locations
-
- 1218.56.01006 Boehringer Ingelheim Investigational Site San Antonio, Texas, United States
- 1218.56.01004 Boehringer Ingelheim Investigational Site Norfolk, Virginia, United States
- 1218.56.11001 Boehringer Ingelheim Investigational Site Montreal, Quebec, Canada
- 1218.56.33003 Boehringer Ingelheim Investigational Site Fort de France Cedex, France
NCT00500955
- Conditions
- Diabetes Mellitus, Diabetes Mellitus, Type 2, Endocrine System Diseases, +3 more
- Locations
-
- GSK Investigational Site Birmingham, Alabama, United States
- GSK Investigational Site Tempe, Arizona, United States
- GSK Investigational Site Fullerton, California, United States
- GSK Investigational Site Long Beach, California, United States
Completed
Rosiglitazone In Subjects With Type 2 Diabetes Mellitus Who Are Inadequately Controlled On Insulin
NCT00329225
- Conditions
- Diabetes Mellitus, Diabetes Mellitus, Type 2, Endocrine System Diseases, +3 more
- Locations
-
- GSK Investigational Site Birmingham, Alabama, United States
- GSK Investigational Site Birmingham, Alabama, United States
- GSK Investigational Site Fairfield, Alabama, United States
- GSK Investigational Site Fultondale, Alabama, United States
Completed
Efficacy and Safety of Empagliflozin (BI 10773) With Metformin in Patients With Type 2 Diabetes
NCT01167881
- Conditions
- Diabetes Mellitus, Diabetes Mellitus, Type 2, Endocrine System Diseases, +3 more
- Locations
-
- 1245.28.10005 Boehringer Ingelheim Investigational Site Phoenix, Arizona, United States
- 1245.28.10012 Boehringer Ingelheim Investigational Site Phoenix, Arizona, United States
- 1245.28.10016 Boehringer Ingelheim Investigational Site Hot Springs, Arkansas, United States
- 1245.28.10003 Boehringer Ingelheim Investigational Site Sacramento, California, United States
NCT00069836
- Conditions
- Diabetes Mellitus, Diabetes Mellitus, Type 2, Endocrine System Diseases, +3 more
- Locations
-
- GSK Investigational Site Vienna, Austria
- GSK Investigational Site Vienna, Austria
- GSK Investigational Site Roubaix, Hauts-de-France, France
- GSK Investigational Site Angers, France
NCT00306644
- Conditions
- Diabetes Mellitus, Diabetes Mellitus, Type 2, Endocrine System Diseases, +5 more
- Locations
-
- GSK Investigational Site Malmö, Sweden
NCT02881164
- Conditions
- Diabetes Mellitus, Diabetes Mellitus, Type 2, Endocrine System Diseases, +5 more
- Locations
-
Not specified